Consun Pharmaceutical Group Ltd. (HK:1681) has released an update.
Consun Pharmaceutical Group Ltd. has announced the National Medical Products Administration’s approval for clinical trials of their SK-08 Tablet, aimed at treating chronic kidney disease, and the drug registration approval for Iodixanol Injection, an isotonic X-ray contrast agent with high safety profiles. These developments are set to enhance the company’s product offerings in the treatment of kidney disease and medical imaging diagnosis, addressing significant unmet medical needs and promising market potential.
For further insights into HK:1681 stock, check out TipRanks’ Stock Analysis page.
